Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 6/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172798 | 0.90 | CA12 (0.57) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL4181151 | 0.89 | CA12 (0.56) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL4183383 | 0.87 | CYP2C9 (0.44) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL4203393 | 0.81 | KDM4E (0.55) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL4186712 | 0.81 | PKLR (0.55) | KDM4EALDH1A1SMN1; SMN2PKLRMEN1 | |
| SCHEMBL4187265 | 0.80 | PKLR (0.52) | PKLR | |
| SCHEMBL4169865 | 0.80 | FASN (0.59) | CCR1 | |
| SCHEMBL1806893 | 0.78 | HRH3 (0.50) | PRSS12MEN1KMT2A | |
| SCHEMBL4177346 | 0.75 | CA12 (0.50) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL4182807 | 0.74 | FASN (0.51) | PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | claimed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | KDM4E 2575/4885CA12 2949/4885CA1 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.